TY - JOUR
T1 - Efficacy of a nurse-led sexual rehabilitation intervention for women with gynaecological cancers receiving radiotherapy
T2 - results of a randomised trial
AU - Suvaal, Isabelle
AU - Hummel, Susanna B.
AU - Mens, Jan Willem M.
AU - Tuijnman-Raasveld, Charlotte C.
AU - Tsonaka, Roula
AU - Velema, Laura A.
AU - Westerveld, Henrike
AU - Cnossen, Jeltsje S.
AU - Snyers, An
AU - Jürgenliemk-Schulz, Ina M.
AU - Lutgens, Ludy C.H.W.
AU - Beukema, Jannet C.
AU - Haverkort, Marie A.D.
AU - Nowee, Marlies E.
AU - Nout, Remi A.
AU - de Kroon, Cor D.
AU - van den Hout, Wilbert B.
AU - Creutzberg, Carien L.
AU - van Doorn, Helena C.
AU - ter Kuile, Moniek M.
N1 - Publisher Copyright:
© The Author(s) 2024.
PY - 2024/9
Y1 - 2024/9
N2 - Background: The multicentre randomised SPARC trial evaluated the efficacy of a nurse-led sexual rehabilitation intervention on sexual functioning, distress, dilator use, and vaginal symptoms after radiotherapy for gynaecological cancers. Methods: Eligible women were randomised to the rehabilitation intervention or care-as-usual. Four intervention sessions were scheduled over 12 months, with concurrent validated questionnaires and clinical assessments. Primary outcome was the Female Sexual Function Index (FSFI). A generalised-mixed-effects model compared groups over time. Results: In total, 229 women were included (n = 112 intervention; n = 117 care-as-usual). No differences in FSFI total scores were found between groups at any timepoint (P = 0.37), with 12-month scores of 22.57 (intervention) versus 21.76 (care-as-usual). The intervention did not significantly improve dilator use, reduce sexual distress or vaginal symptoms compared to care-as-usual. At 12 months, both groups had minimal physician-reported vaginal stenosis; 70% of women were sexually active and reported no or mild vaginal symptoms. After radiotherapy and brachytherapy, 85% (intervention) versus 75% (care-as-usual) of participants reported dilation twice weekly. Discussion: Sexual rehabilitation for women treated with combined (chemo)radiotherapy and brachytherapy improved before and during the SPARC trial, which likely contributed to comparable study groups. Best practice involves a sexual rehabilitation appointment 1 month post-radiotherapy, including patient information, with dilator guidance, preferably by a trained nurse, and follow-up during the first year after treatment. Clinical trial registration: NCT03611517.
AB - Background: The multicentre randomised SPARC trial evaluated the efficacy of a nurse-led sexual rehabilitation intervention on sexual functioning, distress, dilator use, and vaginal symptoms after radiotherapy for gynaecological cancers. Methods: Eligible women were randomised to the rehabilitation intervention or care-as-usual. Four intervention sessions were scheduled over 12 months, with concurrent validated questionnaires and clinical assessments. Primary outcome was the Female Sexual Function Index (FSFI). A generalised-mixed-effects model compared groups over time. Results: In total, 229 women were included (n = 112 intervention; n = 117 care-as-usual). No differences in FSFI total scores were found between groups at any timepoint (P = 0.37), with 12-month scores of 22.57 (intervention) versus 21.76 (care-as-usual). The intervention did not significantly improve dilator use, reduce sexual distress or vaginal symptoms compared to care-as-usual. At 12 months, both groups had minimal physician-reported vaginal stenosis; 70% of women were sexually active and reported no or mild vaginal symptoms. After radiotherapy and brachytherapy, 85% (intervention) versus 75% (care-as-usual) of participants reported dilation twice weekly. Discussion: Sexual rehabilitation for women treated with combined (chemo)radiotherapy and brachytherapy improved before and during the SPARC trial, which likely contributed to comparable study groups. Best practice involves a sexual rehabilitation appointment 1 month post-radiotherapy, including patient information, with dilator guidance, preferably by a trained nurse, and follow-up during the first year after treatment. Clinical trial registration: NCT03611517.
UR - http://www.scopus.com/inward/record.url?scp=85197446547&partnerID=8YFLogxK
U2 - 10.1038/s41416-024-02775-8
DO - 10.1038/s41416-024-02775-8
M3 - Article
C2 - 38961193
AN - SCOPUS:85197446547
SN - 0007-0920
VL - 131
SP - 808
EP - 819
JO - British Journal of Cancer
JF - British Journal of Cancer
IS - 5
ER -